-
Mashup Score: 0Dual tissue and plasma testing to improve detection of actionable variants in patients with solid cancers. - 2 year(s) ago
3017 Background: Next generation sequencing (NGS) of tumor tissue and plasma (circulating tumor DNA [ctDNA]) are used clinically to identify actionable genomic alterations, with implications for treatment selection and disease surveillance. Early studies have observed that solid tumor tissue and ctDNA testing may capture both overlapping and complementary alterations. Using the Tempus database,…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Dual tissue and plasma testing to improve detection of actionable variants in patients with solid cancers. - 2 year(s) ago
3017 Background: Next generation sequencing (NGS) of tumor tissue and plasma (circulating tumor DNA [ctDNA]) are used clinically to identify actionable genomic alterations, with implications for treatment selection and disease surveillance. Early studies have observed that solid tumor tissue and ctDNA testing may capture both overlapping and complementary alterations. Using the Tempus database,…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Dual tissue and plasma testing to improve detection of actionable variants in patients with solid cancers [June 2, 2022] Mackay et al. #ASCO22 Abst 3017 https://t.co/2vARw6GAbP #PrecisionMedicine #LiquidBiopsy #camets @TempusLabs https://t.co/Jr1fO6d1bZ
-
-
Mashup Score: 0Dual tissue and plasma testing to improve detection of actionable variants in patients with solid cancers. - 2 year(s) ago
3017 Background: Next generation sequencing (NGS) of tumor tissue and plasma (circulating tumor DNA [ctDNA]) are used clinically to identify actionable genomic alterations, with implications for treatment selection and disease surveillance. Early studies have observed that solid tumor tissue and ctDNA testing may capture both overlapping and complementary alterations. Using the Tempus database,…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Dual tissue and plasma testing to improve detection of actionable variants in patients with solid cancers [June 2, 2022] Mackay et al. #ASCO22 Abst 3017 https://t.co/2vARw6GAbP #PrecisionMedicine #LiquidBiopsy #camets @TempusLabs https://t.co/pzqXpHP4lV
-
-
Mashup Score: 0
Purpose Broadening trial eligibility to improve accrual and access and to better reflect intended-to-treat populations has been recognized as a priority. Historically, patients with brain metastases have been understudied, because of restrictive eligibility across all phases of clinical trials. Methods In 2016, after a literature search and series of teleconferences, a multistakeholder workshop…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Modernizing #ClinicalTrials I/E: Recs @ASCO @CancerResrch Brain Metastases [10/2/17] Lin et al. @JCO_ASCO https://t.co/Dijym2AVdA #camets
-
-
Mashup Score: 2Dual tissue and plasma testing to improve detection of actionable variants in patients with solid cancers. - 2 year(s) ago
3017 Background: Next generation sequencing (NGS) of tumor tissue and plasma (circulating tumor DNA [ctDNA]) are used clinically to identify actionable genomic alterations, with implications for treatment selection and disease surveillance. Early studies have observed that solid tumor tissue and ctDNA testing may capture both overlapping and complementary alterations. Using the Tempus database,…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Dual tissue and plasma testing to improve detection of actionable variants in patients with solid cancers [June 2, 2022] Mackay et al. #ASCO22 Abst 3017 https://t.co/2vARw6GAbP #PrecisionMedicine #LiquidBiopsy #camets @Tempus
-
-
Mashup Score: 1Dual tissue and plasma testing to improve detection of actionable variants in patients with solid cancers. - 2 year(s) ago
3017 Background: Next generation sequencing (NGS) of tumor tissue and plasma (circulating tumor DNA [ctDNA]) are used clinically to identify actionable genomic alterations, with implications for treatment selection and disease surveillance. Early studies have observed that solid tumor tissue and ctDNA testing may capture both overlapping and complementary alterations. Using the Tempus database,…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Dual tissue and plasma testing to improve detection of actionable variants in patients with solid cancers [June 2, 2022] Mackay et al. #ASCO22 Abst 3017 https://t.co/2vARw6GAbP #PrecisionMedicine #LiquidBiopsy #camets @Tempus https://t.co/CCuH9BHfLa
-
-
Mashup Score: 2Dual tissue and plasma testing to improve detection of actionable variants in patients with solid cancers. - 2 year(s) ago
3017 Background: Next generation sequencing (NGS) of tumor tissue and plasma (circulating tumor DNA [ctDNA]) are used clinically to identify actionable genomic alterations, with implications for treatment selection and disease surveillance. Early studies have observed that solid tumor tissue and ctDNA testing may capture both overlapping and complementary alterations. Using the Tempus database,…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Dual tissue and plasma testing to improve detection of actionable variants in patients with solid cancers [June 2, 2022] Mackay et al. #ASCO22 Abst 3017 https://t.co/2vARw6GAbP #PrecisionMedicine #LiquidBiopsy #camets @Tempus
-
-
Mashup Score: 4Craniospinal irradiation improves leptomeningeal metastasis control - Nature Reviews Clinical Oncology - 2 year(s) ago
Nature Reviews Clinical Oncology – Craniospinal irradiation improves leptomeningeal metastasis control
Source: NatureCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @NatRevClinOncol: Craniospinal irradiation improves leptomeningeal metastasis control: https://t.co/hmr4EXag5i #radonc #camets #BCSM #LC…
-
Craniospinal irradiation improves leptomeningeal metastasis control: https://t.co/hmr4EXag5i #radonc #camets #BCSM #LCSM #breastcancer https://t.co/RjIDwrnoZv
-
-
Mashup Score: 0Dual tissue and plasma testing to improve detection of actionable variants in patients with solid cancers. - 2 year(s) ago
3017 Background: Next generation sequencing (NGS) of tumor tissue and plasma (circulating tumor DNA [ctDNA]) are used clinically to identify actionable genomic alterations, with implications for treatment selection and disease surveillance. Early studies have observed that solid tumor tissue and ctDNA testing may capture both overlapping and complementary alterations. Using the Tempus database,…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Dual tissue and plasma testing to improve detection of actionable variants in patients with solid cancers [June 2, 2022] Mackay et al. #ASCO22 Abst 3017 https://t.co/2vARw6GAbP #PrecisionMedicine #LiquidBiopsy #camets @Tempus https://t.co/dCrnbj1qX6
-
-
Mashup Score: 2Dual tissue and plasma testing to improve detection of actionable variants in patients with solid cancers. - 2 year(s) ago
3017 Background: Next generation sequencing (NGS) of tumor tissue and plasma (circulating tumor DNA [ctDNA]) are used clinically to identify actionable genomic alterations, with implications for treatment selection and disease surveillance. Early studies have observed that solid tumor tissue and ctDNA testing may capture both overlapping and complementary alterations. Using the Tempus database,…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Dual tissue and plasma testing to improve detection of actionable variants in patients with solid cancers [June 2, 2022] Mackay et al. #ASCO22 Abst 3017 https://t.co/2vARw6GAbP #PrecisionMedicine #LiquidBiopsy #camets @Tempus
-
@HenryJOncology @pashtoonkasi @OncoAlert @ASCO @realbowtiedoc @manjuggm @GraceCordovano @marklewismd @fumikochino @IshwariaMD @crisbergerot @paspears88 Dual tissue and plasma testing to improve detection of actionable variants in patients with solid cancers [June 2, 2022] Mackay et al. #ASCO22 Abst 3017 https://t.co/2vARw6GAbP #PrecisionMedicine #LiquidBiopsy #camets @TempusLabs